Perpetual Ltd Trims Astrazeneca Plc Holdings

The institutional investor reduced its stake in the pharmaceutical company by over 60% in Q4 2025.

Apr. 6, 2026 at 9:33am

Got story updates? Submit your updates here. ›

Perpetual Ltd, an institutional investor, decreased its position in shares of Astrazeneca Plc (NYSE:AZN) by 60.3% in the fourth quarter of 2025, according to the company's most recent Form 13F filing with the Securities & Exchange Commission. Perpetual Ltd's holdings in Astrazeneca were valued at $515,000 as of the filing.

Why it matters

This reduction in Perpetual Ltd's Astrazeneca holdings provides insight into the investment strategy and portfolio adjustments of the institutional investor. Tracking changes in major shareholders' positions can offer clues about the market's sentiment towards a company.

The details

Perpetual Ltd sold 8,513 shares of Astrazeneca, leaving the institutional investor with 5,606 shares of the pharmaceutical company's stock. The filing did not disclose the reasons behind Perpetual Ltd's decision to trim its Astrazeneca position.

  • Perpetual Ltd filed the 13F report for the fourth quarter of 2025.

The players

Perpetual Ltd

An institutional investor that decreased its stake in Astrazeneca Plc.

Astrazeneca Plc

A global biopharmaceutical company headquartered in Cambridge, England, that researches, develops, manufactures, and commercializes prescription medicines.

Got photos? Submit your photos here. ›

The takeaway

Perpetual Ltd's reduction in its Astrazeneca holdings provides a data point on the investment decisions of one institutional investor, which could signal broader market sentiment towards the pharmaceutical company. However, without further context, it's difficult to draw definitive conclusions about Astrazeneca's performance or future prospects.